Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from GH Research ( (GHRS) ) is now available.
On March 25, 2026, GH Research PLC reported that full results from its randomized, double-blind, placebo-controlled Phase 2b trial of mebufotenin (GH001) in treatment-resistant depression have been published and peer-reviewed in JAMA Psychiatry. The article details primary and secondary efficacy outcomes, safety and tolerability, and six‑month open‑label extension data, providing a key validation milestone for the program.
The company also disclosed that a supporting manuscript has been accepted for publication in Psychopharmacology Bulletin, showing GH001’s efficacy does not diminish with increasing numbers of prior antidepressant treatment failures. This severity‑independent effect contrasts with the well-known decline in remission rates seen in legacy trials such as STAR*D, reinforcing GH001’s potential to address heavily pretreated TRD patients and underpinning GH Research’s push toward global pivotal trials.
The most recent analyst rating on (GHRS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
The score is held down primarily by pre-revenue financials with widening losses and continued cash burn, partially offset by a very low-leverage balance sheet. Technicals are neutral-to-mildly supportive (price above longer-term averages with neutral momentum), while valuation is constrained by negative earnings and no dividend data.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC is a Dublin-based, clinical-stage biopharmaceutical company focused on developing novel mebufotenin-based therapies for treatment-resistant depression (TRD). Its lead candidate, GH001, is an inhaled formulation designed to deliver rapid antidepressant effects, with the company targeting a practice-changing role in the TRD treatment landscape.
Average Trading Volume: 373,467
Technical Sentiment Signal: Buy
Current Market Cap: $819.4M
See more data about GHRS stock on TipRanks’ Stock Analysis page.